옵션 체인은 다양한 행사가격과 만기일에 대한 Zai Lab의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Zai Lab에 대한 시장 심리를 평가합니다..

Zai Lab (NASDAQ:ZLAB) 주식, 옵션 체인

Zai Lab

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Stuttgart,,Germany,-,08-24-2023:,Person,Holding,Cellphone,With,Website,Of

Equities

Mid Cap

News

Movers

AIFU

APLD

BPMC

CRWV

KYMR

NVCR

RIOT

RXRX

SEZL

ZLAB

어플라이드 디지털, 라이엇 플랫폼스 등 지난주 급등한 중형주 10종목 (6월 2일~6일)

Las,Vegas,,Usa,-,April,13,,2014:,Hertz,Car,Rental

BULL

CERT

MTSR

SBSW

VIST

허츠, 비스타 에너지 등 지난주 급등한 중형주 6종목 (4월 14~18일)

Zai Lab Limited - American Depositary Shares

Zai Lab Ltd

Options

Markets

RIVN

Rivian Automotive Option Alert: Jul 18 $20 Calls at the Ask: 2500 @ $0.12 vs 8445 OI

BMO Capital analyst Keith Bachman maintains Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) with a Market Perform and raises the price target from $175 to $200.

Price Target

Analyst Ratings

ORCL

BMO Capital Maintains Market Perform on Oracle, Raises Price Target to $200

Events

Exclusives

CRLBF

From Benzinga's Cannabis Capital Conference: Cresco Labs CEO, Charlie Bachtell Says Cannabis Was Not On The Administration's First 100 Day List, Says We Need To Find The Opportunity To Let Them Go Through The Initiatives

Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) has outperformed the market over the past 5 years by 37.09% on an annualized basis producing an average annual return of 51.6%. Currently, Vertiv Holdings has a market capitalization of $43.52 billion. 
Buying $1000 In VRT: If an investor had bought $1000 of VRT stock 5 years ago, it would be worth $8,434.64 today based on a price of $114.20 for VRT at the time of writing.
<h3>Vertiv Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749478516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

BMO Capital analyst Ari Klein downgrades Apple Hospitality REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APLE#NYSE">APLE</a>) from Outperform to Market Perform and lowers the price target from $14 to $12.

Downgrades

APLE

BMO Capital Downgrades Apple Hospitality REIT to Market Perform, Lowers Price Target to $12

Baird analyst Andrew Wittmann upgrades ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) from Neutral to Outperform and maintains the price target from $56 to $56.

Upgrades

Baird Upgrades ABM Indus to Outperform, Maintains Price Target to $56

Omada Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) closed its first day of trading at $23 per share on Friday, a 21% jump from the IPO price of $19 per share.
On Thursday, Omada Health <a href="https://www.businesswire.com/news/home/20250605376361/en/Omada-Health-Announces-Pricing-of-Initial-Public-Offering" target="_blank" rel="noreferrer noopener">priced</a> its initial public offering of 7.9 million at $19/share. The company filed its initial prospectus in May and updated the document with an expected pricing range of $18 to $20 per share. 
The company raised $150 million in its IPO. Reuters reported Omada Health&#8217;s valuation hit $1.28 billion.
Omada&#8217;s revenue increased 57% in the first quarter of 2025 to $55 million from $35.1 million a year earlier, according to its prospectus. For 2024, revenue rose 38% to $169.8 million from $122.8 million the previous year.
Also Read: <a href="https://www.benzinga.com/news/ipos/25/05/45581582/hinge-health-skyrockets-on-wall-street-debut-signals-comeback-for-health-tech-ipos-tilts-things-towards-potentially-more-listings-says-analyst" target="_blank" rel="noreferrer noopener">Hinge Health Skyrockets On Wall Street Debut, Signals Comeback For Health-Tech IPOs: &#8216;&#8230;Tilts Things&#8230;Towards Potentially More Listings,&#8217; Says Analyst</a>
The company&#8217;s net loss narrowed to $9.4 million in the first quarter from $19 million a year ago.
Omada launched its initial virtual program in <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">diabetes prevention and weight health</a> in 2012.
The company delivers virtual care between doctor visits, providing an engaging, personalized, and integrated experience for members designed to improve their health while delivering value for employers, health plans, health systems, pharmacy benefit managers (PBMs), and other entities that cover the cost of programs.
According to its <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1611115/000119312525129904/d785770ds1a.htm" rel="noreferrer noopener">S-1</a> filing, the company had 2,000 customers and more than 679,000 members enrolled in one or more programs as of 31 March. Omada says it has supported more than 1 million members since its launch.
The company expanded its virtual care programs to target prediabetes, hypertension, and musculoskeletal conditions.
The company estimates that about 20 million people have benefits coverage for one or more Omada programs. According to the company&#8217;s S-1 filing, this represents about 14% of the self-insured insurance market, 9% of the fully insured market, 1% of the Medicare Advantage market, and 1% of the PBM market.
Wall Street Journal, citing President Wei-Li Shao, writes that Omada leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro have sparked a renewed focus on health problems that can stem from obesity.
GLP-1s are expected to be a significant tailwind as more employers are rolling out reimbursement plans for the drugs, CEO&nbsp;Sean Duffy <a target="_blank" href="https://www.wsj.com/health/pharma/omada-health-ipo-to-price-at-19-a-share-as-glp-1s-fuel-interest-becac4b7" rel="noreferrer noopener">told</a> WSJ. Omada, which signs contracts with employers to offer as a benefit to their workers, aims to be a complementary service that helps patients navigate taking GLP-1s.
Omada&#8217;s IPO is the second digital health IPO in weeks following an extended drought for the industry.
In May, digital physical therapy startup Hinge Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HNGE#NYSE">HNGE</a>) debuted on the <a href="https://www.benzinga.com/pressreleases/25/05/b45555364/hinge-health-announces-pricing-of-initial-public-offering" target="_blank" rel="noreferrer noopener">New York Stock Exchange</a>. Hinge Health priced its IPO of 13.7 million shares at $32 per share.
Price Action: OMDA stock is trading lower by 0.43% to $22.90 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45830632/ex-goldman-executive-on-circles-168-ipo-spike-dont-rush-to-buy-stock-as-bankers-engineer-a-pop-cites-facebook-example" target="_blank" rel="noreferrer noopener">Ex-Goldman Executive On Circle&#8217;s 168% IPO Spike: Don&#8217;t Rush To Buy Stock As Bankers Engineer A &#8216;Pop&#8217; — Cites Facebook Example</a></li>
</ul>
Photo via Shutterstock

Health Care

IPOs

General

HNGE

OMDA

Virtual Care Firm Omada Health Leverages GLP-1 Trend For $150 Million NASDAQ Debut

Keybanc analyst Bradley Thomas maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Overweight and raises the price target from $105 to $110.

Keybanc Maintains Overweight on Walmart, Raises Price Target to $110

KLTO

Klotho Neurosciences Shares Resume Trade

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 0.2% on Monday.
Following the market opening Monday, the Dow traded down 0.23% to 42,664.42 while the NASDAQ gained 0.05% to 19,538.86. The S&amp;P 500 also fell, dropping, 0.10% to 5,994.22.
Check This Out: <a href="https://www.benzinga.com/news/25/06/45834978/jim-cramer-says-kinder-morgan-is-good-calls-this-communication-services-stock-a-winner">Jim Cramer Says Kinder Morgan Is &#8216;Good,&#8217; Calls This Communication Services Stock A &#8216;Winne</a>r&#8217;
Leading and Lagging Sectors Information technology shares jumped by 0.6% on Monday.
In trading on Monday, utilities stocks fell by 0.8%.
Top Headline
Motorcar Parts of America, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPAA#NASDAQ">MPAA</a>) posted better-than-expected earnings for the fourth quarter on Monday.
The company posted adjusted earnings of 28 cents per share, beating market estimates of 20 cents per share. The company's quarterly sales came in at $193.10 million, versus expectations of $190.70 million.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares shot up 311% to $0.8430 after the company said gene therapy boosted lifespan by 20% in mice, eyes anti-aging breakthrough.</li>
<li>Shares of Know Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNW#NYSE">KNW</a>) got a boost, surging 103% to $3.1701. Know Labs shares jumped 205% on Friday after the company announced that entered into an agreement to be acquired by Goldeneye 1995. Also, the company announced a Bitcoin treasury strategy.</li>
<li>Twin Hospitality Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWNP#NASDAQ">TWNP</a>) shares were also up, gaining 61% to $6.60.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares dropped 43% to $2.40 after the company announced the pricing of an offering of 1,054,604 shares at $2.50 per share.</li>
<li>Shares of Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) were down 41% to $0.2373 after the company announced the pricing of a $4.3 million offering of 406,755 shares and approximately 14 million pre-funded warrants with series A and B Warrants at $0.30 per unit.</li>
<li>The Children&#8217;s Place, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) was down, falling 28% to $4.9101 as the company posted weaker-than-expected results for its first quarter after the closing bell on Friday.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $64.44 while gold traded down 0.2% at $3,339.40.
Silver traded up 1.2% to $36.575 on Monday, while copper rose 1.2% to $4.9070.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.1%, while Spain's IBEX 35 Index fell 0.1%. London's FTSE 100 slipped 0.2%, Germany's DAX 40 fell 0.6% and France's CAC 40 fell 0.2% during the session.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei gaining 0.92%, Hong Kong's Hang Seng Index jumping 1.63%, China's Shanghai Composite gaining 0.43% and India's BSE Sensex gaining 0.31%.
Economics
U.S. wholesale inventories rose 0.2% month-over-month for April.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45835438/top-3-financial-stocks-that-may-collapse-in-june">Top 3 Financial Stocks That May Collapse In June</a> </li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

Intraday Update

MPAA

NUWE

PLCE

RSLS

TWNP

US Stocks Mixed; Motorcar Parts of America Posts Upbeat Earnings

Shareholders as at the ex-dividend date of 12 June 2025 will be eligible to receive any potential special dividend distributions relating to Tembo transactions&nbsp;
Corresponding record date will be 13 June 2025
LONDON, June 09, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>, "VivoPower" or the "Company"))) today announced that it has set an ex-dividend date of 12 June 2025 pertaining to any potential future dividend distributions regarding transactions involving Tembo e LV B.V. ("Tembo").
Shareholders who hold VivoPower shares as of the close of business on 12 June 2025 will be entitled to receive any potential future special dividend distributions relating to Tembo. Shareholders purchasing VivoPower shares on or after the ex-dividend date will not be eligible for the distribution.
Any potential future special dividend distributions relating to the Caret business unit will be advised separately.
Further details regarding potential special dividend distributions, including the amount and ratio will be provided when appropriate. There is no guarantee that any special dividend distributions will be made.

Dividends

VVPR

VivoPower Sets June 12, 2025 Ex-Dividend Date And June 13 Record Date For Potential Special Dividend Distributions Tied To Tembo Transactions

Smith+Nephew ((LSE:SN, NYSE:<a href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023.
With the ability to be used with or without the Posterior Cruciate Ligament (PCL), procedural trends are moving away from Posterior Stabilized (PS) design types to more bone-conservative Cruciate Retaining (CR) femoral designs. The reduction of operating steps also creates the potential for greater efficiency and shorter time in the OR for both surgeon and patient.&nbsp;
The medial stabilized design aims to maintain stability with a larger anterior medial lip and medial pivot kinematics similar to the natural knee.
The medial stabilized insert for LEGION TKS is available in the US on a limited basis, with a full commercial release later in 2025. The system will also be introduced in Canada in 2026.

Smith+Nephew Introduces New Medial Stabilized Insert For LEGION Total Knee System

Keybanc analyst Jeffrey Hammond maintains Gates Industrial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTES#NYSE">GTES</a>) with a Overweight and raises the price target from $23 to $26.

GTES

Keybanc Maintains Overweight on Gates Industrial Corp, Raises Price Target to $26

Investors with a lot of money to spend have taken a bullish stance on CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CRWD, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 17 uncommon options trades for CrowdStrike Holdings.
This isn't normal.
The overall sentiment of these big-money traders is split between 41% bullish and 35%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $184,070, and 14 are calls, for a total amount of $483,833.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $480.0 for CrowdStrike Holdings over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for CrowdStrike Holdings options trades today is 719.53 with a total volume of 541.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for CrowdStrike Holdings's big money trades within a strike price range of $150.0 to $480.0 over the last 30 days.
<h3>CrowdStrike Holdings Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749477841_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$15.8</td>
<td>$14.65</td>
<td>$15.14</td>
<td>$470.00</td>
<td>$75.8K</td>
<td>1.7K</td>
<td align="right">60</td>
</tr>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.8</td>
<td>$9.4</td>
<td>$9.84</td>
<td>$465.00</td>
<td>$73.8K</td>
<td>223</td>
<td align="right">75</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/27/25</td>
<td>$63.0</td>
<td>$60.05</td>
<td>$61.63</td>
<td>$400.00</td>
<td>$61.6K</td>
<td>17</td>
<td align="right">10</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$101.5</td>
<td>$98.5</td>
<td>$100.91</td>
<td>$400.00</td>
<td>$50.4K</td>
<td>25</td>
<td align="right">2</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$50.7</td>
<td>$48.55</td>
<td>$49.64</td>
<td>$420.00</td>
<td>$49.6K</td>
<td>463</td>
<td align="right">10</td>
</tr>
</tbody>
</table>

<h3>About CrowdStrike Holdings</h3>
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
Following our analysis of the options activities associated with CrowdStrike Holdings, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of CrowdStrike Holdings</h3>
<ul>
<li>With a trading volume of 455,721, the price of CRWD is down by -0.74%, reaching $464.93.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 79 days from now.</li>
</ul>
<h3>What The Experts Say On CrowdStrike Holdings</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $452.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Raymond James lowers its rating to Outperform with a new price target of $485. 
&#x2A; Maintaining their stance, an analyst from Stifel continues to hold a Buy rating for CrowdStrike Holdings, targeting a price of $480. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on CrowdStrike Holdings, maintaining a target price of $505. 
&#x2A; An analyst from Roth Capital has decided to maintain their Buy rating on CrowdStrike Holdings, which currently sits at a price target of $420. 
&#x2A; An analyst from Bernstein downgraded its action to Market Perform with a price target of $371. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for CrowdStrike Holdings with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

CRWD

CrowdStrike Holdings Options Trading: A Deep Dive into Market Sentiment

Whales with a lot of money to spend have taken a noticeably bullish stance on Hims &amp; Hers Health.
Looking at options history for Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 58% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $56,370 and 10, calls, for a total amount of $1,326,341.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $60.0 for Hims &amp; Hers Health, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Hims &amp; Hers Health stands at 1735.67, with a total volume reaching 1,252.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Hims &amp; Hers Health, situated within the strike price corridor from $3.0 to $60.0, throughout the last 30 days.
<h3>Hims &amp; Hers Health Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749477835_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$52.45</td>
<td>$51.65</td>
<td>$51.96</td>
<td>$3.00</td>
<td>$519.6K</td>
<td>583</td>
<td align="right">80</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$54.05</td>
<td>$51.55</td>
<td>$51.88</td>
<td>$3.00</td>
<td>$415.0K</td>
<td>583</td>
<td align="right">0</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$9.3</td>
<td>$9.2</td>
<td>$9.2</td>
<td>$60.00</td>
<td>$91.9K</td>
<td>3.5K</td>
<td align="right">105</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$10.6</td>
<td>$10.3</td>
<td>$10.42</td>
<td>$60.00</td>
<td>$74.9K</td>
<td>815</td>
<td align="right">98</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/13/25</td>
<td>$2.69</td>
<td>$2.52</td>
<td>$2.69</td>
<td>$55.00</td>
<td>$53.8K</td>
<td>1.9K</td>
<td align="right">436</td>
</tr>
</tbody>
</table>

<h3>About Hims &amp; Hers Health</h3>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
After a thorough review of the options trading surrounding Hims &amp; Hers Health, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Hims &amp; Hers Health</h3>
<ul>
<li>Trading volume stands at 4,420,543, with HIMS's price down by -1.84%, positioned at $55.29.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 56 days.</li>
</ul>
<h3>Expert Opinions on Hims &amp; Hers Health</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $65.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Needham persists with their Buy rating on Hims &amp; Hers Health, maintaining a target price of $65. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Hims &amp; Hers Health options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with WMT, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 14 options trades for Walmart.
This isn't normal.
The overall sentiment of these big-money traders is split between 28% bullish and 64%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $60,580, and 13, calls, for a total amount of $422,435.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $90.0 to $100.0 for Walmart over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Walmart's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Walmart's whale activity within a strike price range from $90.0 to $100.0 in the last 30 days. 
<h3>Walmart Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749477829_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.24</td>
<td>$1.18</td>
<td>$1.24</td>
<td>$98.00</td>
<td>$71.6K</td>
<td>2.7K</td>
<td>588</td>
</tr>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.1</td>
<td>$6.05</td>
<td>$6.1</td>
<td>$100.00</td>
<td>$60.5K</td>
<td>2.3K</td>
<td>100</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.54</td>
<td>$0.5</td>
<td>$0.5</td>
<td>$100.00</td>
<td>$50.0K</td>
<td>34.2K</td>
<td>4.0K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$11.45</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$95.00</td>
<td>$36.4K</td>
<td>1.4K</td>
<td>1</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$8.5</td>
<td>$8.3</td>
<td>$8.44</td>
<td>$90.00</td>
<td>$33.8K</td>
<td>382</td>
<td>40</td>
</tr>
</tbody>
</table>

<h3>About Walmart</h3>
Walmart is a leading retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 locations globally. Walmart generated over $460 billion in domestic namesake sales in fiscal 2025, with Sam's Club contributing another $90 billion to the company's top line. Internationally, Walmart generated $120 billion in sales. The retailer serves around 270 million customers globally each week.
Having examined the options trading patterns of Walmart, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Walmart</h3>
<ul>
<li>Trading volume stands at 1,449,019, with WMT's price down by -0.03%, positioned at $97.44.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 66 days.</li>
</ul>
<h3>Expert Opinions on Walmart</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $112.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Walmart with a target price of $110. 
&#x2A; An analyst from Telsey Advisory Group persists with their Outperform rating on Walmart, maintaining a target price of $115. 
&#x2A; Consistent in their evaluation, an analyst from Telsey Advisory Group keeps a Outperform rating on Walmart with a target price of $115. 
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on Walmart, maintaining a target price of $107. 
&#x2A; An analyst from DA Davidson persists with their Buy rating on Walmart, maintaining a target price of $117. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Walmart with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On Walmart

Klotho Neurosciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 417.1%

MIND Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIND#NASDAQ">MIND</a>) is preparing to release its quarterly earnings on Tuesday, 2025-06-10. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect MIND Technology to report an earnings per share (EPS) of $0.08.
Anticipation surrounds MIND Technology's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.07 in the last quarter, leading to a 26.47% increase in the share price on the following day.
Here's a look at MIND Technology's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2025</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.18</td>
<td>0.13</td>
<td>0.02</td>
<td>0.3</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.25</td>
<td>2.87</td>
<td>-0.11</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>26.0%</td>
<td>42.0%</td>
<td>5.0%</td>
<td>-20.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1749477784_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of MIND Technology were trading at $6.96 as of June 06. Over the last 52-week period, shares are up 57.37%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MIND/earnings">To track all earnings releases for MIND Technology visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MIND

MIND Technology's Earnings: A Preview

PetMed Express (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETS#NASDAQ">PETS</a>) is preparing to release its quarterly earnings on Tuesday, 2025-06-10. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect PetMed Express to report an earnings per share (EPS) of $-0.06.
The announcement from PetMed Express is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.03, leading to a 14.04% drop in the share price on the subsequent day.
Here's a look at PetMed Express's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0</td>
<td>-0.05</td>
<td>-0.09</td>
<td>-0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.03</td>
<td>0.11</td>
<td>0.18</td>
<td>-0.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-14.000000000000002%</td>
<td>36.0%</td>
<td>-14.000000000000002%</td>
<td>-11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1749477770_0.png" alt="eps graph" />
<h3>Performance of PetMed Express Shares</h3>
Shares of PetMed Express were trading at $3.96 as of June 06. Over the last 52-week period, shares are down 15.5%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/PETS/earnings">To track all earnings releases for PetMed Express visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PETS

What to Expect from PetMed Express's Earnings

<ul>
<li>Site would take advantage of existing infrastructure and more than a century of partnership with Anderson County</li>
<li>Proposal will be first request by company to build new generation in the Palmetto State in a decade</li>
<li>Plans support intent by state leaders to address growth and economic success by advancing new electricity capacity in the state</li>
</ul>
GREENVILLE, S.C., June 9, 2025 /PRNewswire/ -- Duke Energy announced today the company's intent to submit an application to the Public Service Commission of South Carolina (PSCSC) for approval to build a new natural gas power plant in Anderson County.

Duke Energy Intends To Submit Application To Public Service Commission Of South Carolina For Approval To Build New Natural Gas Power Plant In Anderson County

Press Releases

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

Zai Lab Announces Participation in Investor Conferences in June 2025

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Comments

Zai Lab

Zai Lab (ZLAB) 옵션

Zai Lab (NASDAQ:ZLAB) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌